Peptic Ulcer Disease
Peptic Ulcer Disease
Purpose of Review: This review attempts to contextualize some of the clinically important publications of the last 2 years as they relate to the broad topic of dyspepsia and peptic ulcer disease, both Helicobacter pylori and nonsteroidal anti-inflammatory drug-related.
Recent Findings: This review includes findings which provide insight with regard to the triaging of dyspeptic subjects, information on new proton pump inhibitor drugs and H. pylori eradication 'rescue regimens'. The 'COX-2 debacle' is discussed and new data relating to the efficacy of co-therapy strategies for the prevention of nonsteroidal anti-inflammatory drug gastropathy are presented, while the use of antiplatelet agents as 'safe' substitutes for aspirin cardioprophylaxis is questioned. The important issue of proton pump inhibitor safety and nonsteroidal anti-inflammatory drug enteropathy are addressed.
Summary: The review provides a summary and interpretation of literature pertaining to the above issues, and should provide a point of departure for clinical decision-making relevant to these issues.
This review focuses on papers of clinical significance published during the period 2005-2006. Primary topics addressed are dyspepsia, the treatment of peptic ulcer disease, Helicobacter pylori and the broad topic of nonsteroidal anti-inflammatory drug (NSAID)/aspirin gastroenteropathy. The principal aim is to highlight and introduce new data published in this period and to contextualize some of the important developments in this period, based on relevant publications.
Abstract and Introduction
Abstract
Purpose of Review: This review attempts to contextualize some of the clinically important publications of the last 2 years as they relate to the broad topic of dyspepsia and peptic ulcer disease, both Helicobacter pylori and nonsteroidal anti-inflammatory drug-related.
Recent Findings: This review includes findings which provide insight with regard to the triaging of dyspeptic subjects, information on new proton pump inhibitor drugs and H. pylori eradication 'rescue regimens'. The 'COX-2 debacle' is discussed and new data relating to the efficacy of co-therapy strategies for the prevention of nonsteroidal anti-inflammatory drug gastropathy are presented, while the use of antiplatelet agents as 'safe' substitutes for aspirin cardioprophylaxis is questioned. The important issue of proton pump inhibitor safety and nonsteroidal anti-inflammatory drug enteropathy are addressed.
Summary: The review provides a summary and interpretation of literature pertaining to the above issues, and should provide a point of departure for clinical decision-making relevant to these issues.
Introduction
This review focuses on papers of clinical significance published during the period 2005-2006. Primary topics addressed are dyspepsia, the treatment of peptic ulcer disease, Helicobacter pylori and the broad topic of nonsteroidal anti-inflammatory drug (NSAID)/aspirin gastroenteropathy. The principal aim is to highlight and introduce new data published in this period and to contextualize some of the important developments in this period, based on relevant publications.
Source...